{"entry":{"id":"6772c64cec6d4d1e","medicine":"Osimertinib (Tagrisso)","tumour":"Non-small cell lung cancer","histology":null,"setting":"Adjuvant","requirement":"EGFR exon 19 deletions or exon 21 (L858R)","biomarker_must_be_absent":false,"other_biomarkers":[],"regimen":"Monotherapy","conditions":"After complete tumour resection; Stage IB-IIIA","conditional_approval":false,"needs_review":false,"link":"https://oncolabels.com/?open=6772c64cec6d4d1e","tumour_as_labelled":"NSCLC","label_sentence":"the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (see section 5.1).","cut_off":"exon 19 deletion or exon 21 (L858R) substitution mutation","scoring_system":null,"age_group":"adult","smpc":"https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf"},"product":{"brand":"Tagrisso","ema_product_number":"EMEA/H/C/004124","smpc_en":"https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf","label_updated":"2026-08-18"},"trace":null,"dataset":{"version":"52f637a50d","ema_data_of":"2026-11-05","checked":"2026-11-05","notice":"EU label indications from EMA product information (SmPC section 4.1), generated by AI and not reviewed by a person. A non-commercial reference for education and research, not medical advice; the current SmPC takes precedence."}}